Founded in 2017 and based in Watertown, Massachusetts, Disc Medicine is a clinical-stage biopharmaceutical company that aims to transform the treatment of hematologic disorders. By targeting the hepcidin or iron metabolism axis, the company is developing first-in-class therapies that address iron loading anemia and ineffective red blood cell production. Supported by a team of experienced scientists and industry experts, Disc Medicine is building a portfolio of therapeutic candidates that affect fundamental pathways of red blood cell biology. The company has attracted investment from Atlas Venture, Brian MacDonald, Novo Ventures, and Access Biotechnology.